Literature DB >> 33585522

Editorial: Interstitial Lung Disease in the Context of Systemic Disease: Pathophysiology, Treatment and Outcomes.

Peter Korsten1, Maximilian F Konig2, Björn Tampe1, Mehdi Mirsaeidi3.   

Abstract

Entities:  

Keywords:  autoimmune diseases; interstitial lung disease; myositis; rheumatoid arthritis; systemic sclerosis (scleroderma)

Year:  2021        PMID： 33585522      PMCID： PMC7874049          DOI： 10.3389/fmed.2020.644075

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN： 2296-858X


× No keyword cloud information.
  10 in total

1.  An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.

Authors:  Aryeh Fischer; Katerina M Antoniou; Kevin K Brown; Jacques Cadranel; Tamera J Corte; Roland M du Bois; Joyce S Lee; Kevin O Leslie; David A Lynch; Eric L Matteson; Marta Mosca; Imre Noth; Luca Richeldi; Mary E Strek; Jeffrey J Swigris; Athol U Wells; Sterling G West; Harold R Collard; Vincent Cottin
Journal:  Eur Respir J       Date:  2015-07-09       Impact factor: 16.671

Review 2.  Pulmonary manifestations of Sjögren's syndrome.

Authors:  Thomas Flament; Adrien Bigot; Benjamin Chaigne; Helene Henique; Elisabeth Diot; Sylvain Marchand-Adam
Journal:  Eur Respir Rev       Date:  2016-06

3.  Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients.

Authors:  Carlos Fernández-Díaz; Javier Loricera; Santos Castañeda; Raquel López-Mejías; Clara Ojeda-García; Alejandro Olivé; Samantha Rodríguez-Muguruza; Patricia E Carreira; Trinidad Pérez-Sandoval; Miriam Retuerto; Evelin C Cervantes-Pérez; Bryan J Flores-Robles; Blanca Hernández-Cruz; Ana Urruticoechea; Olga Maíz-Alonso; Luis Arboleya; Gema Bonilla; Íñigo Hernández-Rodríguez; Desirée Palma; Concepción Delgado; Rosa Expósito-Molinero; Ana Ruibal-Escribano; Belén Álvarez-Rodríguez; Juan Blanco-Madrigal; José A Bernal; Paloma Vela-Casasempere; Manuel Rodríguez-Gómez; Concepción Fito; Francisco Ortiz-Sanjuán; Javier Narváez; Manuel Moreno; Mireia López-Corbeto; Natalia Mena-Vázquez; Clara Aguilera-Cros; Susana Romero-Yuste; Sergi Ordóñez; Ignacio Villa-Blanco; M Carmen Gonzélez-Vela; Víctor Mora-Cuesta; Natalia Palmou-Fontana; José L Hernández; Miguel A González-Gay; Ricardo Blanco
Journal:  Semin Arthritis Rheum       Date:  2018-01-06       Impact factor: 5.532

Review 4.  Spectrum of Fibrotic Lung Diseases.

Authors:  Marlies Wijsenbeek; Vincent Cottin
Journal:  N Engl J Med       Date:  2020-09-03       Impact factor: 91.245

5.  Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis.

Authors:  Xiaojing Xing; Anqi Li; Chengxin Li
Journal:  Respir Med       Date:  2020-09-01       Impact factor: 3.415

6.  Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry.

Authors:  Cristina Vadillo; Maria Asuncion Nieto; Fredeswinda Romero-Bueno; Leticia Leon; Olga Sanchez-Pernaute; Maria Jesus Rodriguez-Nieto; Dalifer Freites; Juan Angel Jover; Jose Luis Álvarez-Sala; Lydia Abasolo
Journal:  Rheumatology (Oxford)       Date:  2020-08-01       Impact factor: 7.580

7.  MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.

Authors:  Pierre-Antoine Juge; Joyce S Lee; Esther Ebstein; Hiroshi Furukawa; Evgenia Dobrinskikh; Steven Gazal; Caroline Kannengiesser; Sébastien Ottaviani; Shomi Oka; Shigeto Tohma; Naoyuki Tsuchiya; Jorge Rojas-Serrano; Montserrat I González-Pérez; Mayra Mejía; Ivette Buendía-Roldán; Ramcés Falfán-Valencia; Enrique Ambrocio-Ortiz; Effrosyni Manali; Spyros A Papiris; Theofanis Karageorgas; Dimitrios Boumpas; Katarina Antoniou; Coline H M van Moorsel; Joanne van der Vis; Yaël A de Man; Jan C Grutters; Yaping Wang; Raphaël Borie; Lidwine Wemeau-Stervinou; Benoît Wallaert; René-Marc Flipo; Hilario Nunes; Dominique Valeyre; Nathalie Saidenberg-Kermanac'h; Marie-Christophe Boissier; Sylvain Marchand-Adam; Aline Frazier; Pascal Richette; Yannick Allanore; Jean Sibilia; Claire Dromer; Christophe Richez; Thierry Schaeverbeke; Huguette Lioté; Gabriel Thabut; Nadia Nathan; Serge Amselem; Martin Soubrier; Vincent Cottin; Annick Clément; Kevin Deane; Avram D Walts; Tasha Fingerlin; Aryeh Fischer; Jay H Ryu; Eric L Matteson; Timothy B Niewold; Deborah Assayag; Andrew Gross; Paul Wolters; Marvin I Schwarz; Michael Holers; Joshua J Solomon; Tracy Doyle; Ivan O Rosas; Cornelis Blauwendraat; Mike A Nalls; Marie-Pierre Debray; Catherine Boileau; Bruno Crestani; David A Schwartz; Philippe Dieudé
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

8.  Interstitial Lung Disease with Anti-melanoma Differentiation-associated Protein 5 Antibody: Rapidly Progressive Perilobular Opacity.

Authors:  Haruka Chino; Akimasa Sekine; Tomohisa Baba; Hideya Kitamura; Tae Iwasawa; Koji Okudela; Tamiko Takemura; Harumi Itoh; Shinji Sato; Yasuo Suzuki; Takashi Ogura
Journal:  Intern Med       Date:  2019-06-07       Impact factor: 1.271

9.  Anti-ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma.

Authors:  João Pedro Ferreira; Isabel Almeida; António Marinho; Conceição Cerveira; Carlos Vasconcelos
Journal:  ISRN Rheumatol       Date:  2012-03-27

10.  Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's.

Authors:  Augustine S Lee; R Hal Scofield; Katherine Morland Hammitt; Nishant Gupta; Donald E Thomas; Teng Moua; Kamonpun Ussavarungsi; E William St Clair; Richard Meehan; Kieron Dunleavy; Matt Makara; Steven E Carsons; Nancy L Carteron
Journal:  Chest       Date:  2020-10-16       Impact factor: 9.410
  10 in total
  1 in total

Review 1.  Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations.

Authors:  Tihong Shao; Xiaodong Shi; Shanpeng Yang; Wei Zhang; Xiaohu Li; Jingwei Shu; Shehabaldin Alqalyoobi; Amir A Zeki; Patrick S Leung; Zongwen Shuai
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.